tofersen

Tofersen

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">tofersen</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>tofersen</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

Introduction

Tofersen is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Tofersen (brand name: QALSODY) is an intrathecally administered [antisense-oligonucleotide-therapy](/therapeutics/antisense-oligonucleotide-therapy) designed to treat [als](/diseases/amyotrophic-lateral-sclerosis) caused by mutations in the [@ionis2023]
[superoxide dismutase 1 (SOD1) gene. On April 25, 2023, the FDA granted accelerated approval to tofersen, making it the first therapy to [@miller2022]
target a genetic cause of ALS [@biogen2023] [@miller2020]
[@ionis2023]. [@als]
Developed jointly by Biogen and Ionis Pharmaceuticals, tofersen represents a paradigm shift in ALS therapeutics—from symptom management to [@washington2025]
precision medicine targeting the underlying genetic cause of disease. [@shefner2024]

...

Tofersen

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">tofersen</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>tofersen</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

Introduction

Tofersen is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Tofersen (brand name: QALSODY) is an intrathecally administered [antisense-oligonucleotide-therapy](/therapeutics/antisense-oligonucleotide-therapy) designed to treat [als](/diseases/amyotrophic-lateral-sclerosis) caused by mutations in the [@ionis2023]
[superoxide dismutase 1 (SOD1) gene. On April 25, 2023, the FDA granted accelerated approval to tofersen, making it the first therapy to [@miller2022]
target a genetic cause of ALS [@biogen2023] [@miller2020]
[@ionis2023]. [@als]
Developed jointly by Biogen and Ionis Pharmaceuticals, tofersen represents a paradigm shift in ALS therapeutics—from symptom management to [@washington2025]
precision medicine targeting the underlying genetic cause of disease. [@shefner2024]

SOD1 mutations account for approximately 2% of all ALS cases and roughly 12–20% of familial ALS cases. These mutations lead to the [@bjornsson2025]
production of misfolded, toxic SOD1 protein that accumulates in [motor [neurons](/entities/neurons), contributing to neurodegeneration through [oxidative-stress](/mechanisms/oxidative-stress), [mitochondrial-dysfunction](/mechanisms/mitochondrial-dysfunction), and [protein-aggregation](/mechanisms/protein-aggregation) [@miller2022] [@benatar2022]

Neurofilament Light Chain as a Biomarker

[Neurofilament light chain ([NfL](/biomarkers/neurofilament-light-chain-nfl)))[/proteins/[nfl-protein](/proteins/nfl-protein) is a structural protein released from damaged axons into cerebrospinal fluid and blood. Elevated plasma [@omar2025]
[neurofilament-light](/biomarkers/neurofilament-light-chain-nfl)) concentrations are a sensitive indicator of active neurodegeneration and have emerged as a key biomarker in ALS. Tofersen's
accelerated approval was based on its ability to significantly reduce plasma [neurofilament-light](/biomarkers/neurofilament-light-chain-nfl)) levels, which served as a surrogate biomarker reasonably
likely to predict clinical benefit [@biogen2023]
[@miller2022]
[@als]

Clinical Evidence

Phase 1–2 Trial

The initial Phase 1–2 ascending-dose trial enrolled 50 adults with SOD1-ALS and evaluated tofersen at doses of 20 mg, 40 mg, 60 mg, and 100 mg. The study demonstrated dose-dependent reductions in CSF SOD1 protein concentrations and was generally well tolerated. The 100 mg dose achieved the greatest SOD1 reduction and was selected for the Phase 3 trial [@miller2020]

• Early vs. delayed treatment: Participants who received placebo during VALOR and switched to tofersen in the OLE showed greater cumulative functional decline than those who received tofersen from the start, suggesting an advantage to earlier treatment initiation [@shefner2024]
• Sustained biomarker reduction: SOD1 and [neurofilament-light](/biomarkers/neurofilament-light-chain-nfl)) reductions were maintained throughout long-term treatment

Case Series Evidence

A case series from Iceland documented that treatment with tofersen resulted in nonprogressive chronic ALS in some patients, with stabilization of ALSFRS-R scores over extended follow-up periods. These real-world observations provide additional support for tofersen's disease-modifying potential in SOD1-ALS [@bjornsson2025].

ATLAS Trial (Presymptomatic Treatment)

The ATLAS study (NCT04856982) is a groundbreaking Phase 3, randomized, placebo-controlled trial evaluating tofersen in presymptomatic
carriers of SOD1 mutations—individuals who carry a disease-causing mutation but have not yet developed clinical symptoms. The trial targets
carriers of SOD1 variants associated with high or complete penetrance and rapid disease progression who show biomarker evidence of disease
activity (elevated plasma NfL) [@benatar2022].

Key details:

• Target enrollment: Approximately 150 adults
• Eligibility: Presymptomatic SOD1 variant carriers with elevated plasma [neurofilament-light](/biomarkers/neurofilament-light-chain-nfl))
• Primary endpoint: Time to clinical onset of ALS
• Sites: 14 countries worldwide
• Estimated primary completion: 2026

The ATLAS trial represents a bold test of whether presymptomatic intervention can delay or prevent clinical onset of ALS, which would have profound implications for genetic counseling, newborn screening, and the broader neurodegenerative disease field [@benatar2022].

Safety and Adverse Effects

The most common adverse effects of tofersen include:

• Procedure-related events: Headache (26%), post-lumbar puncture syndrome (21%), back pain (19%), and pain in extremity (13%) related to the intrathecal injection procedure
• Myelitis: Serious but uncommon inflammatory events involving the spinal cord, including transverse myelitis and radiculitis, have been observed. Patients should be monitored for symptoms such as back pain, weakness, and sensory changes
• Papilledema and intracranial pressure: Cases of increased intracranial pressure and papilledema have been reported; regular ophthalmological monitoring is recommended
• CSF abnormalities: Elevated CSF white blood cell counts and protein levels have been observed in some patients
• Injection site reactions: Pain, erythema, and inflammation at the injection site [@biogen2023]

[@miller2022]

Significance and Future Directions

Tofersen represents several important advances in neurodegenerative disease treatment:

Precision medicine in ALS: Tofersen is the first ALS therapy to target a specific genetic cause, validating the precision medicine approach in motor neuron diseases

ASO platform validation: The success of tofersen builds on the [antisense-oligonucleotide-therapy](/therapeutics/antisense-oligonucleotide-therapy) platform that has also yielded nusinersen for [spinal-muscular-atrophy](/diseases/spinal-muscular-atrophy), demonstrating broad applicability of ASO technology in motor neuron diseases

Biomarker-guided therapy: The use of plasma [neurofilament-light](/biomarkers/neurofilament-light-chain-nfl)) as a surrogate endpoint for accelerated approval established a precedent for biomarker-driven regulatory pathways in ALS

Presymptomatic intervention paradigm: The ATLAS trial may establish the feasibility of treating neurodegenerative diseases before clinical symptom onset, a concept with implications for [alzheimers](/diseases/alzheimers-disease), [huntington-pathway](/mechanisms/huntington-pathway), and other genetic neurodegenerative conditions

Research is also exploring ASO approaches targeting other ALS genes, including [c9orf72](/genes/c9orf72), [fus](/entities/fus), and [atxn2](/genes/atxn2), which could extend the precision medicine approach to a larger proportion of ALS patients.

See Also

• [antisense-oligonucleotide-therapy](/therapeutics/antisense-oligonucleotide-therapy)
• [edaravone](/therapeutics/edaravone)
• [riluzole](/therapeutics/riluzole)

Background

The study of Tofersen has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Mechanism of Action Flowchart

Key Steps in Tofersen Mechanism

Target Identification: SOD1 mutations produce toxic misfolded protein

ASO Delivery: Intrathecal administration reaches CNS

mRNA Degradation: Tofersen binds SOD1 mRNA, recruiting RNase H1

Protein Reduction: Less toxic SOD1 protein is produced

Neuroprotection: Motor neurons are protected from degeneration

Biomarker Response: NfL levels decrease with effective treatment

Mechanism of Action Flowchart

Key Steps in Tofersen Mechanism

Target Identification: SOD1 mutations produce toxic misfolded protein

ASO Delivery: Intrathecal administration reaches CNS

mRNA Degradation: Tofersen binds SOD1 mRNA, recruiting RNase H1

Protein Reduction: Less toxic SOD1 protein is produced

Neuroprotection: Motor neurons are protected from degeneration

Biomarker Response: NfL levels decrease with effective treatment

References

Unknown, Biogen. (2023). FDA Grants Accelerated Approval for QALSODY (tofersen) for SOD1-ALS. [Biogen Press Release (2023)

Unknown, Ionis Pharmaceuticals. (2023). FDA approves QALSODY (tofersen) as the first treatment targeting a genetic cause of ALS. [Ionis Press Release (2023)

Miller TM, et al., (2022). Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 387(12), 1099–1110. [NEJM (2022)

Miller T, et al., (2020). Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 383(2), 109–119. [NEJM (2020)

Unknown, The ALS Association. Tofersen. [ALS Association (n.d.)

Unknown, Washington University. (2025). New ALS drug stabilizes decline with improved strength, mobility for some. [WashU Source (2025)

Shefner JM, et al., (2024). Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis. JAMA Neurology. [PMC12723595 (2024)

Bjornsson HT, et al., (2025). Treating SOD1-ALS with tofersen results in nonprogressive chronic ALS—a case series from Iceland. Journal of Neurology. [Springer (2025)

[Benatar M, et al., (2022). Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. Neurotherapeutics, 19(4), 1248–1258. [PubMed (2022)](https://pubmed.ncbi.nlm.nih.gov/35585374/)

Omar MMA, et al., (2025). Concurrent nanotherapeutics and regulatory updates for ALS: a focused review for orphan drug (Tofersen). International Journal of Pharmaceutics. [PMC12639972 (2025)